MedTrace Logo

HepaSphere Interventional Therapy Using Digital Subtraction Angiography（DSA） for Liver Cancer

NCT02447263 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 87

Last updated 2016-02-25

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and efficacy of HepaSphere interventional therapy using digital subtraction angiography（DSA） for liver cancer.

Conditions

Interventions

PROCEDURE

interventional therapy

liver cancer patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）

Sponsors & Collaborators

  • Fuda Cancer Hospital, Guangzhou

    lead OTHER

Principal Investigators

  • Lizhi Liu, PhD · Fuda Cancer Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-05-31
Primary Completion
2016-02-29
Completion
2016-02-29

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02447263 on ClinicalTrials.gov